Literature DB >> 8948304

Intravenous immunoglobulin as sole therapy for systemic vasculitis.

D R Jayne1, C M Lockwood.   

Abstract

High-dose, pooled, i.v. immunoglobulin (IVIg) is a potential, alternative treatment for Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) which has shown promise in the treatment of refractory disease when administered with continuing immunosuppression. This study of six new patients with antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis and early disease, without threatened vital organ function, examined the therapeutic response to treatment with IVIg alone. IVIg was well tolerated and all six patients had early reductions in disease activity. Four entered full, clinical remission which lasted for at least 1 yr, while in two the responses were partial and transient, and they subsequently required conventional treatment. After 16-48 months of follow-up, two of the four patients in full remission relapsed, but the other two have remained well.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8948304     DOI: 10.1093/rheumatology/35.11.1150

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  26 in total

Review 1.  Clinical trials review: vasculitis.

Authors:  D K Ledford
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Two rare causes of posterior ischaemic optic neuropathy: eosinophilic fasciitis and Wegener's granulomatosis.

Authors:  B Paul; A M McElvanney; S Agarwal; F E Bruckner; W Ayliffe
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

4.  [Multiple, in part ulcerated nodules on the neck and legs of a 60 year old woman].

Authors:  R Aschoff; J Laske; C Pfeiffer; G Wozel; M Meurer
Journal:  Hautarzt       Date:  2003-05-15       Impact factor: 0.751

Review 5.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

6.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.

Authors:  M G Danieli; M Cappelli; G Malcangi; F Logullo; A Salvi; G Danieli
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

Review 7.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 8.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

9.  Wegener's granulomatosis: clinical and laboratory results of a university hospital study of 20 patients from Turkey.

Authors:  Zeynep Ozbalkan; Sedat Kiraz; M Akif Ozturk; A Ihsan Ertenli; Sule Apras; Meral Calguneri
Journal:  Clin Rheumatol       Date:  2005-12-15       Impact factor: 2.980

Review 10.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.